Here are two new pieces of news for Senetek.
Date: February 25, 1997
Senetek PLC Cites Two Factual Errors in Barron's Article, 'Exciting Drugs'
ST. LOUIS, Feb. 24 /PRNewswire/ -- Senetek PLC (Nasdaq: SNTKY), in
response to many investor inquiries today, has elected to set the record
straight and correct two factual errors about the company and its INVICORP(TM)
drug therapy for treating erectile dysfunction that appear in the Feb. 24,
1997 issue of Barron's:
Barron's factual error #1: "Other manufacturers have been researching
variations on prostaglandin, including ... Senetek..."
Correction: Senetek's drug, INVICORP, is NOT prostaglandin. Its new drug
therapy for treating erectile dysfunction (ED) in males, INVICORP, is an
injectable formulation of vasoactive intestinal polypeptide (VIP) in
combination with the adrenergic drug phentolamine, administered with a
proprietary state-of-the-art autoinjector that renders the self-injection
process exceptionally easy and unobtrusive to perform and helps ensure
accurate, safe delivery of medication.
Fact: More than 200 U.K. patients currently are being prescribed
Senetek's INVICORP under their physician's responsibility due to the
significant advantages offered by the drug. Senetek expects to conclude these
clinical trials soon and submit Product Licensing Applications (PLAs) by April
for approval to market the drug in a number of European countries. Pan-
European approval then will be sought through a centralized European procedure
during the second half of 1997.
Fact: The results of a clinical investigation with INVICORP (previously
known as Resurgam(TM)) appeared in the Journal of Urology during 1992. The
study involved 52 ED patients performing a total of 1,380 self-injections with
INVICORP (Resurgam). All the patients were able to achieve erection in
conjunction with sexual stimulation. There were no cases of priapism,
fibrosis, pain or other serious complications. Following ejaculation, the
erections subsided normally. The rate of patient dropout from the INVICORP
(Resurgam) treatment program was less than 20 percent -- a far lower rate of
discontinuation than that reported with papaverine (approximately 50 percent)
or prostaglandin El (70-80 percent).
Barron's factual error #2: "...whose shares have doubled on the NASD
Bulletin Board..."
Correction: Senetek's stock has been traded on the NASDAQ Small Cap
Market under the symbol "SNTKY" since 1986. It never has traded as a Bulletin
Board stock.
"In fact we agree with the Barron's article about prostaglandin not
necessarily being the therapy treatment of choice. That is why we chose to
develop a neurotransmitter (VIP). We are not a me-too drug. We believe
INVICORP represents a significant improvement over all other treatments, both
licensed and under development, for the same ED indications," said Anthony J.
Cataldo, chairman and chief executive officer of Senetek PLC. "It is the only
treatment incorporating a novel autoinjector, offering ease of use and
painless administration, allowing patients to avoid the apprehension normally
associated with injection therapy. We look forward to an opportunity to
update Barron's on Senetek's progress." |
